Bionano Genomics (BNGO) Stock Price, News & Analysis

Company Overview

Bionano Genomics, Inc. is a commercial-stage genomics analysis company focused on advancing research and clinical applications through high-resolution genome mapping. Founded in the mid-2000s and headquartered in San Diego, California, the company developed its flagship Saphyr® system to empower scientists and clinicians with detailed structural insight into DNA molecules. Bionano’s mission centers on enabling the discovery of previously inaccessible genomic variations, particularly in areas such as rare disease, oncology and agricultural biotechnology.

The company’s core offering, the Saphyr system, combines specialized reagents, chip consumables and proprietary software to deliver ultra-long DNA molecule imaging and analysis. Saphyr is designed to detect large structural variants, copy number variations and complex rearrangements with high sensitivity. In addition to instruments and consumables, Bionano operates a service bureau, providing contract research and custom analysis for pharmaceutical companies, academic institutions and diagnostic laboratories seeking targeted or discovery-driven genome mapping solutions.

Bionano’s technologies are utilized by a global customer base that spans North America, Europe, Asia and Latin America. The platform has been adopted in collaborative programs with leading research centers, biopharma organizations and healthcare providers, driving initiatives in precision medicine, translational research and agricultural genomics. The company also collaborates with regulatory bodies and academic consortia to advance standards for structural variant characterization and reporting.

Led by President and CEO Erik Holmlin and supported by a board of directors with deep expertise in biotechnology and life-science instrumentation, Bionano Genomics leverages its scientific advisory panel and experienced management team to guide product development and market expansion. The company completed its initial public offering in 2018 and continues to invest in R&D, aiming to broaden the accessibility of genome mapping and to accelerate discoveries across research and clinical communities worldwide.

Key Stats

• Today's Range: $3.31 to $3.43
• 50-Day Range: $3.20 to $3.95
• 52-Week Range: $2.68 to $41.10
• Volume: 58,698 shs
• Average Volume: 166,416 shs
• Market Capitalization: $11.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Bionano Genomics Stock Analysis - MarketRank™

Bionano Genomics scored higher than 41% of companies evaluated by MarketBeat, and ranked 696th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Bionano Genomics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bionano Genomics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bionano Genomics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bionano Genomics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bionano Genomics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.87% of the float of Bionano Genomics has been sold short.

Short Interest Ratio / Days to Cover

Bionano Genomics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionano Genomics has recently decreased by 9.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bionano Genomics does not currently pay a dividend.

Dividend Growth

Bionano Genomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.87% of the float of Bionano Genomics has been sold short.

Short Interest Ratio / Days to Cover

Bionano Genomics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bionano Genomics has recently decreased by 9.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

Bionano Genomics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Bionano Genomics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BNGO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bionano Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bionano Genomics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.90% of the stock of Bionano Genomics is held by insiders.

Percentage Held by Institutions

Only 11.35% of the stock of Bionano Genomics is held by institutions.

BNGO Stock Analysis - Frequently Asked Questions

How have BNGO shares performed this year?

Bionano Genomics' stock was trading at $17.3040 on January 1st, 2025. Since then, BNGO shares have decreased by 80.5% and is now trading at $3.38.

How were Bionano Genomics' earnings last quarter?

Bionano Genomics, Inc. (NASDAQ:BNGO) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.49) by $2.34. The company had revenue of $6.46 million for the quarter, compared to analysts' expectations of $6.25 million. Bionano Genomics had a negative trailing twelve-month return on equity of 125.75% and a negative net margin of 294.05%.
Read the conference call transcript.

When did Bionano Genomics' stock split?

Shares of Bionano Genomics reverse split on the morning of Monday, January 27th 2025.The 1-60 reverse split was announced on Wednesday, January 22nd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Bionano Genomics IPO?

Bionano Genomics (BNGO) raised $16 million in an IPO on the week of August 20th 2018. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Maxim Group acted as the underwriters for the IPO and LifeSci Capital was co-manager.

How do I buy shares of Bionano Genomics?

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bionano Genomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionano Genomics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), Waste Connections (WCN), AU Optronics (AUOTY), American Water Works (AWK) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:BNGO
• CIK: 1411690
• Web: www.bionanogenomics.com
• Phone: (858) 888-7600
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bionano Genomics: $7.00
• High Price Target: $10.00
• Low Price Target: $4.00
• Potential Upside/Downside: +105.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($138.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$112.02 million
• Net Margins: -294.05%
• Pretax Margin: -293.84%
• Return on Equity: -125.75%
• Return on Assets: -71.96%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 1.70
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $30.78 million
• Price / Sales: 0.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.12 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 3,360,000
• Free Float: 3,334,000
• Market Cap: $11.46 million
• Optionable: Optionable
• Beta: 2.20